Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide

Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide,  is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly

Continue Reading

Diabetes Drug, Jentadueto, Reaches UK Market

Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor

Continue Reading

Jentadueto Receives European Commission Marketing Authorisation

European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European

Continue Reading

US FDA Approves Erbitux for KRAS Wild-Type Cancer

A new indication for Bristol-Myers Squibb (BMS) and Eli Lilly’s Erbitux, which is sold outside the USA by Merck KGaA, has been approved by US regulators. Meanwhile, the US Food and Drug Administration (FDA) have also cleared the first KRAS companion diagnostic test, the therascreen KRAS diagnostic kit which was developed by the Netherlands-based firm,

Continue Reading

Final NICE Approval for Eli Lilly’s Bydureon

The UK’s National Institute for Health and Clinical Excellence (NICE) announced yesterday that they had confirmed in final guidance a endorsement of the use of Eli Lilly’s Bydureon (prolonged-release exenatide) in triple-therapy regimens as a treatment option for people with type 2 diabetes. The director of NICE’s centre for health technology evaluation, Professor Carole Longson,

Continue Reading

Eli Lilly Forecast Tough 2012 for Earnings

Although Eli Lilly expects to meet or exceed their current earnings per share guidance for 2011 of $3.84-$3.89, the company has announced that profits for 2012 will be $3.10-$3.20 per share, well below analysts’ estimations. The latter prediction is based on 2012 revenues of $21.8-$22.8 billion, which includes an expected reduction of over $3 billion

Continue Reading

NICE Draft OK for Eli Lilly Diabetes Drug

The UK’s National Institute for Health and Clinical Excellence (NICE) have issued an initial recommendation of approval for the use of Eli Lilly’s Bydureon (exenatide prolonged-release suspension for injection) in triple-therapy options for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate. NICE commented that Bydureon improves glycaemic control in

Continue Reading